Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Gottschalk, Nina ^a   Lang, Stephan ^a   Kimmig, Rainer ^a   Singh, Mahavir ^b   Brandau, Sven ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b LIONEX DIAGNOSTICS AND THERAPEUTICS GMBH   (Germany)

Author keywords

BCG; Cetuximab; Immunotherapy; NK cell; Ovarian cancer; PstS 1

Indexed keywords

CETUXIMAB; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; MYCOBACTERIUM ANTIGEN; PSTS 1 ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL ADHESION; CELL FUNCTION; CELL INTERACTION; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MONOCYTE; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; OVARY CANCER; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TARGET CELL;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, BACTERIAL; ATP-BINDING CASSETTE TRANSPORTERS; BACTERIAL PROTEINS; BLOTTING, WESTERN; CELL COMMUNICATION; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-15; INTERLEUKIN-18; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MOLECULAR WEIGHT; MONOCYTES; MYCOBACTERIUM TUBERCULOSIS; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84866889282     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-451     Document Type: Article

References (32)

1. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan J, Sarosdy MF, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 1991, 325:1205-1209. 10.1056/NEJM199110243251703, 1922207.
2. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989, 141:22-29.
3. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999, 161:1124-1127. 10.1016/S0022-5347(01)61607-0, 10081852.
4. Cymes MFJ, Fleischmann JD, Smith E. Invasive bladder cancer treated with intravesical BCG. J Urol 1992, 147:273.
5. Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, Jocham D, Ratliff TL, Bohle A. NK cells are essential for effective BCG immunotherapy. Int J Cancer 2001, 92:697-702. 10.1002/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z, 11340575.
6. Suttmann H, Jacobsen M, Reiss K, Jocham D, Bohle A, Brandau S. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol 2004, 172:1490-1495. 10.1097/01.ju.0000131944.52354.63, 15371877.
7. Marcenaro E, Ferranti B, Falco M, Moretta L, Moretta A. Human NK cells directly recognize Mycobacterium bovis via TLR2 and acquire the ability to kill monocyte-derived DC. Int Immunol 2008, 20:1155-1167. 10.1093/intimm/dxn073, 18596023.
8. Vordermeier HM, Coombes AG, Jenkins P, McGee JP, O'Hagan DT, Davis SS, Singh M. Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. Vaccine 1995, 13:1576-1582. 10.1016/0264-410X(95)00084-E, 8578845.
9. Braibant M, Lefevre P, de Wit L, Peirs P, Ooms J, Huygen K, Andersen AB, Content J. A Mycobacterium tuberculosis gene cluster encoding proteins of a phosphate transporter homologous to the Escherichia coli Pst system. Gene 1996, 176:171-176. 10.1016/0378-1119(96)00242-9, 8918249.
10. Sanger C, Busche A, Bentien G, Spallek R, Jonas F, Bohle A, Singh M, Brandau S. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer. BMC Cancer 2004, 4:86. 10.1186/1471-2407-4-86, 544192, 15566565.
11. Jung SB, Yang CS, Lee JS, Shin AR, Jung SS, Son JW, Harding CV, Kim HJ, Park JK, Paik TH, Song CH, Jo EK. The mycobacterial 38-kilodalton glycolipoprotein antigen activates the mitogen-activated protein kinase pathway and release of proinflammatory cytokines through Toll-like receptors 2 and 4 in human monocytes. Infect Immun 2006, 74:2686-2696. 10.1128/IAI.74.5.2686-2696.2006, 1459749, 16622205.
12. Sanchez A, Espinosa P, Esparza MA, Colon M, Bernal G, Mancilla R. Mycobacterium tuberculosis 38-kDa lipoprotein is apoptogenic for human monocyte-derived macrophages. Scand J Immunol 2009, 69:20-28. 10.1111/j.1365-3083.2008.02193.x, 19140873.
13. Shams H, Barnes PF, Weis SE, Klucar P, Wizel B. Human CD8+ T cells recognize epitopes of the 28-kDa hemolysin and the 38-kDa antigen of mycobacterium tuberculosis. J Leukoc Biol 2003, 74:1008-1014. 10.1189/jlb.0403138, 12972510.
14. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989, 143:3183-3191.
15. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001, 97:3146-3151. 10.1182/blood.V97.10.3146, 11342442.
16. Screpanti V, Wallin RP, Grandien A, Ljunggren HG. Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 2005, 42:495-499. 10.1016/j.molimm.2004.07.033, 15607805.
17. Trinchieri G. Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin Immunol 1995, 7:83-88. 10.1006/smim.1995.0012, 7579198.
18. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007, 26:503-517. 10.1016/j.immuni.2007.03.006, 2084390, 17398124.
19. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immun 2001, 2:293-299.
20. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999, 5:909-916.
21. Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, Sismondi P, Love S, Scott WN, Williams AR, Lessells AM, Macleod KG, Smyth JF, Miller WR. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 1996, 73:301-306. 10.1038/bjc.1996.53, 2074444, 8562334.
22. Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, Zeillinger R. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 1997, 17:613-619.
23. Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol 2008, 110:140-145. 10.1016/j.ygyno.2008.04.018, 18554700.
24. Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, Lewandowski G, Mannel RS, . Gynecologic Oncology Group Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a gynecologic oncology group study. Gynecol Oncol 2008, 108:493-499. 10.1016/j.ygyno.2007.11.029, 2744339, 18191993, Gynecologic Oncology Group.
25. Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 2009, 113:21-27. 10.1016/j.ygyno.2008.12.003, 2741166, 19162309.
26. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999, 162:4511-4520.
27. Miller JS, Oelkers S, Verfaillie C, McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood 1992, 80:2221-2229.
28. Borg C, Jalil A, Laderach D, Maruyama K, Wakasugi H, Charrier S, Ryffel B, Cambi A, Figdor C, Vainchenker W, Galy A, Caignard A, Zitvogel L. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 2004, 104:3267-3275. 10.1182/blood-2004-01-0380, 15242871.
29. Chalifour A, Jeannin P, Gauchat JF, Blaecke A, Malissard M, N'Guyen T, Thieblemont N, Delneste Y. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood 2004, 104:1778-1783. 10.1182/blood-2003-08-2820, 15166032.
30. Kloss M, Decker P, Baltz KM, Baessler T, Jung G, Rammensee HG, Steinle A, Krusch M, Salih HR. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. J Immunol 2008, 181:6711-6719.
31. Varughese J, Cocco E, Bellone S, Bellone M, Todeschini P, Carrara L, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Gynecol Oncol 2011, 122:171-177. 10.1016/j.ygyno.2011.03.002, 3104081, 21453957.
32. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004, 294:15-22. 10.1016/j.jim.2004.08.008, 15604012.